title: Comparison of pre-treatment CYFRA 21 - 1 and SCC-Antigen assay in primary cervical carcinoma - a preliminary report.
abstract: CYFRA21 - 1, a fragment of cytokeratin19, has been widely assessed as a serum marker of squamous malignancies. Previous studies using CYFRA21 - 1 and SCC-Antigen have shown mixed results but have indicated a better predictive prognostic value for SCC-Ag as compared to CYFRA21-1. The aim of our prospective, observational, pilot study was to evaluate the role of CYFRA21-1 and SCC-Ag in primary cervical carcinoma. Pre-operative serum CYFRA21-1 and SCC-Ag were measured (n = 14) in women with cervical carcinoma and correlated with staging, clinico-pathological parameters and prognostic data. Logistic regression analysis with CYFRA 21 - 1 test status (positive or negative) as a dependent variable showed that nodal metastases (p = 0.001) and lymphovascular space invasion (LVSI) (p = 0.005) were significant predictors, whereas stage and SCC-Ag levels were not significant. There was also no statistically significant correlation between SCC-Ag and CYFRA21-1 levels. If larger studies confirm these preliminary results, the option of laparoscopic surgical staging in patients with raised CYFRA21-1 levels could be considered.
authors.affiliation: Northern Gynaecological Oncology Center, Queen Elisabeth Hospital, Gateshead, UK. sunithamurali69@yahoo.com
authors.forename: S
authors.initials: S
authors.lastname: Puthucode-Easwaran
authors.forename: R
authors.initials: R
authors.lastname: Naik
authors.forename: R
authors.initials: R
authors.lastname: Athavale
authors.forename: G
authors.initials: G
authors.lastname: Handley
authors.forename: A
authors.initials: A
authors.lastname: Lopes
authors.forename: K
authors.initials: K
authors.lastname: Godfrey
authors.forename: M
authors.initials: M
authors.lastname: Hatem
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000473:pathology; D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood; D018196:Carcinoma, Adenosquamous / Q000097:blood / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000473:pathology; D005260:Female; D006801:Humans; D053539:Keratin-19; D007633:Keratins; D008207:Lymphatic Metastasis; D008875:Middle Aged; D010865:Pilot Projects; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D015843:Serpins / Q000097:blood*; D002583:Uterine Cervical Neoplasms / Q000097:blood* / Q000473:pathology
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D053539:Keratin-19; D015843:Serpins; C102012:antigen CYFRA21.1; C051072:squamous cell carcinoma-related antigen; D007633:Keratins